Immune Regulation of COVID-19 Infection in Cancer and Autoimmunity

摘要： Emory U54 SeroNET U54计划是一个多学科计划，将 经验丰富的调查团队解决与免疫有关的基本问题 SARS CoV-2，特别是在癌症和自身免疫患者中。这支球队有很长一段时间 在病毒感染背景下的基础研究和转译研究的先前工作的跟踪记录， 疫苗和癌症。该计划包括3个互动项目和两个基本的 除管理核心外，还包括核心。项目1中的研究(由Sanz领导)将研究 传染性非典型肺炎患者SARS CoV-2特异性B细胞应答的生物学研究 自身免疫，特别关注卵泡外B细胞途径。项目中的研究 2(由Sekaly和Wrammert领导)将研究炎症环境在调节 抗病毒免疫和长期记忆反应的发展。研究项目： 项目3(由Dhodapkar和Ahmed领导)将重点研究 癌症治疗，特别是B/血浆患者的B/浆细胞去除治疗 肺癌患者的细胞恶性肿瘤和免疫检查点阻断。这些 研究还将为研究未来SARS CoV-2的免疫反应奠定基础 疫苗适用于自身免疫病患者和癌症患者。这些计划是 由具有以下经验的活动核心(以Roback和Neish为首)提供支持 监测对SARS CoV-2的免疫力。总而言之，该计划不仅将提供基本的 对COVID免疫发病机制的见解，也为该联盟提供了 接触独特的患者群体，具有较高的COVID相关死亡风险。

Abstract: The Emory U54 SeroNET U54 program is a multidisciplinary program that brings together experienced team of investigators to tackle fundamental issues relating to immunity to SARS CoV-2, particular in patients with cancer and autoimmunity. The team has a long track record of prior work in basic and translational studies in the setting of viral infections, vaccines and cancer. The program consists of 3 interacting projects and two essential cores in addition to the administrative core. Studies in project 1 (led by Sanz) will study the biology of SARS CoV-2 specific effector B cell responses in patients with autoimmunity, with a particular focus on extrafollicular B cell pathway. Studies in project 2 (led by Sekaly and Wrammert) will study the role of inflammatory milieu in regulating antiviral immunity and in the development of long term memory responses. Studies in project 3 (led by Dhodapkar and Ahmed) will focus on studying the impact of specific cancer therapies, in particular B/plasma cell depleting therapies in patients with B/plasma cell malignancies, and immune checkpoint blockade in patients with lung cancer. These studies will also set the stage for studying immune responses to future SARS CoV-2 vaccines in patients with autoimmunity as well as cancer patients. The programs are supported by active cores (led by Roback and Neish) which have experience with monitoring immunity to SARS CoV-2. Together, this program will not only provide basic insights into immune-pathogenesis of COVID, but also provide the consortium with access to unique patient populations at higher risk of COVID-related mortality.